



Quetiapine Extended-Release Tablets

Type of Posting	Revision Bulletin
Posting Date	16-Aug-2023
Official Date	17-Aug-2023
Expert Committee	Small Molecules 4

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 4 Expert Committee has revised the Quetiapine Extended-Release Tablets monograph. The purpose of this revision is to add *Dissolution Test 12* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). Clarifications/updates have been included in the preparation of the *0.05 M phosphate buffer solution*, *Buffer stage medium*, and *Acid stage sample solution* in *Dissolution Test 12*. The revision also necessitates a change in the table numbering in the test for *Organic Impurities*.

The Quetiapine Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact V. Durga Prasad, Senior scientist II, +91 40 4448 8723 or durgaprasad.v@usp.org.